Advanced Technologies and Intellectual Property Trends in ADC Research and Development

Advanced Technologies and Intellectual Property Trends in ADC Research and Development


Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment by combining the targeting power of monoclonal antibodies with the potency of cytotoxic agents. This whitepaper explores the latest advancements in ADC technology, including antibody selection, linker development, and payload optimization, as well as global market trends and patent landscapes. With over 200 ADC candidates in clinical trials and significant investments from leading pharmaceutical companies, the field is rapidly evolving. Despite its potential, ADC therapy faces challenges such as premature payload release and immune-related side effects, driving the need for continued innovation in conjugation methods and delivery technologies.

Discover the latest breakthroughs shaping the future of ADC therapy—read the full whitepaper now!

 






Patsnap is transforming how the world innovates with next generation AI. Since 2007, Patsnap's mission is to empower R&D and IP teams to unlock insights, accelerate discoveries, and protect breakthroughs with unprecedented speed and precision. Smart AI agents, the most comprehensive innovation database, robust APIs, and AI-powered SaaS all at your fingertips. Enterprises, law firms, research institutions, and government agencies rely on Patsnap to accelerate discoveries, strengthen IP strategies, and gain a competitive edge.